EN DE
Watch CAMP4 THERAPEUTICS CORPORATION for free: we tell you when fair value or trend changes.
Data-driven stock valuation

CAMP4 THERAPEUTICS CORPORATION (CAMP) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of CAMP4 THERAPEUTICS CORPORATION stock $2.91, price $4.33, that is 32.8% below the price, quality 29 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US13463J1016

CT CAMP4 THERAPEUTICS CORPORATION logo Thin data Nov 11, 2026

CAMP4 THERAPEUTICS CORPORATION

CAMP · US
Expensive, weak quality

Our calculation puts a fair price 33% below what the stock costs today.

Revenue last quarter +139% vs. a year ago.
Insiders bought $99,051 (6M) · sold $2.5M
Fair value $2.91 · Overvalued
Quality 29/100
Weak Growth (revenue 5y −59.2 %/yr in USD)
Negative free cash flow
Trails peers (1/7)
Narrow moat 5/100 · thin data
Thin data
Estimate
Watch CAMP4 THERAPEUTICS CORPORATION for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$11.74 $1.35 Fair Value $2.91 Oct 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

25‑month range $1.35 – $11.74 · fair‑value band $2.18 – $3.63 · the $4.33 price screens above the $2.91 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 11, 2026.

Follow CAMP4 THERAPEUTICS in your weekly email

Every Wednesday you see whether CAMP4 THERAPEUTICS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.

Show moreShow less

The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018.

The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Stock analysis

CAMP4 THERAPEUTICS CORPORATION (CAMP) currently trades at $4.33, while our estimate is $2.91, 33% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $2.18 (bear) to $3.63 (bull), the price of $4.33 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

CAMP4 THERAPEUTICS CORPORATION reported revenue of $3.5M in FY2025 versus $296M in FY2021, a compound −67.0%/yr. Reported net income was −$80.4M in FY2025.

Key figures

Market cap $294M Micro · P/S ratio 55.3 · EPS (TTM) $−2.11 · Return on equity −146% · Return on assets (EBIT) −50.8% (5-year average) · Operating margin −739% · Revenue (TTM) $5.3M · Revenue growth (YoY) +139%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (low confidence).

What moves the price

The share trades about 39% below its 52-week high and 49% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −33%, CAMP screens richer than that median.

Fair Value

Bear $2.18 Fair Value $2.91 Bull $3.63
Price $4.33 · Downside -32.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 58
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 64
Debt, balance sheet and risk of trouble
Investment 72
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 31
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 35
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 4 officers or directors bought shares worth $99,051, most recently on Aug 31, 2026. Over the same period, 2 people sold shares worth $2.5M. Buying cluster

  • BuyKelly GoldChief Financial Officer2× since Aug 3, 2026: 16,551 shares, avg. $3.05$50,409Aug 31, 2026
  • SaleAndrew J. SchwabDirector3× since Aug 19, 2026: 591,875 shares, avg. $4.22$2.5MAug 27, 2026
  • SaleDaniel TardiffChief Scientific Officer1,738 shares at $4.76$8,273Aug 19, 2026
  • BuyJosh Mandel-BrehmChief Executive Officer, Director6,551 shares at $1.65$10,809Aug 3, 2026
  • BuyYuri MaricichChief Medical Officer6,551 shares at $1.65$10,809Aug 3, 2026
  • BuyRichard A YoungDirector16,378 shares at $1.65$27,024Aug 3, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 6/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+436.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−77.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−59.2%
Start year 2020 (pandemic). Over 10 years: −35.5% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1.3% (2020) → −1,488.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CAMP screens overvalued: fair value 33% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare CAMP4 THERAPEUTICS CORPORATION with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −32.8% · Below median
Profitability
Return on assets −68.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 138.9% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 6.17× · Priciest 25%
P/S (12 months) 55.32× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs CAMP
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs CAMP
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs CAMP
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs CAMP
argenx SE ARGX $971.55 $908.40 −7% vs CAMP
CSL Limited CSL A$201.68 A$181.40 −10% vs CAMP
Moderna, Inc MRNA $250.83 $158.70 −37% vs CAMP
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs CAMP
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs CAMP
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs CAMP

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CAMP4 THERAPEUTICS CORPORATION: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CAMP4 THERAPEUTICS CORPORATION Fair Value". https://www.fairvalue-calculator.com/stock/CAMP

Frequently asked questions

Is CAMP4 THERAPEUTICS CORPORATION (CAMP) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $2.91 versus a price of $4.33, about 33% lower (overvalued).
What is the fair value of CAMP?
Our estimate for CAMP4 THERAPEUTICS CORPORATION is $2.91 (as of Nov 11, 2026), built from audited fundamentals. The current price: $4.33.
What is the quality score of CAMP?
CAMP4 THERAPEUTICS CORPORATION has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CAMP4 THERAPEUTICS CORPORATION (CAMP)?
Our calculated price target is the estimate of $2.91 (as of Nov 11, 2026). Cautious scenario $2.18, optimistic scenario $3.63. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the CAMP4 THERAPEUTICS CORPORATION stock forecast for 2026?
Our estimate puts fair value at $2.91, about 33% lower versus a price of $4.33 (overvalued). Cautious scenario $2.18, optimistic scenario $3.63. The calculation is refreshed regularly with new filings.
What is the revenue of CAMP4 THERAPEUTICS CORPORATION (CAMP)?
CAMP4 THERAPEUTICS CORPORATION reported trailing-twelve-month revenue of about $5.3M (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of CAMP4 THERAPEUTICS CORPORATION (CAMP)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CAMP4 THERAPEUTICS CORPORATION it is $2.91 per share (as of Nov 11, 2026), against a price of $4.33.
Is CAMP4 THERAPEUTICS CORPORATION stock overvalued or undervalued in 2026?
As of Nov 11, 2026, CAMP trades above its calculated fair value: price $4.33, fair value $2.91, a gap of about −33% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CAMP?
No. The price is what the market pays today ($4.33); the fair value is what the company's own numbers justify ($2.91). For CAMP4 THERAPEUTICS CORPORATION the two are $1.42 per share apart. That gap is exactly why we show both numbers side by side.
How much is CAMP4 THERAPEUTICS CORPORATION worth?
The market values CAMP4 THERAPEUTICS CORPORATION at about $294M (market capitalisation, as of Nov 11, 2026). Per share that is $4.33; our models calculate a fair value of $2.91 per share.
What do the bullish and bearish scenarios say about CAMP?
Our models span a range for CAMP4 THERAPEUTICS CORPORATION: cautious scenario $2.18, base $2.91, optimistic $3.63 per share (as of Nov 11, 2026, price $4.33). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of CAMP4 THERAPEUTICS CORPORATION (CAMP)?
Balance-sheet figures for CAMP4 THERAPEUTICS CORPORATION (as of Nov 11, 2026): return on equity −146.1%. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is CAMP from its 52-week high?
CAMP4 THERAPEUTICS CORPORATION trades at $4.33, about 39% below its 52-week high of $7.13 and 49% above the low of $2.90 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $2.91 is for.
Which stocks are comparable to CAMP4 THERAPEUTICS CORPORATION?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CAMP4 THERAPEUTICS CORPORATION stock attractive at the current price?
The data as of Nov 11, 2026: price $4.33, calculated fair value $2.91 (−33%), Quality Score 29/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. CAMP4 THERAPEUTICS CORPORATION itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CAMP4 THERAPEUTICS CORPORATION (CAMP)?
The closing price on Nov 10, 2026 was $4.33. Our estimate is $2.91, about 33% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CAMP4 THERAPEUTICS CORPORATION right now?
The price sits above even our optimistic bull case ($3.63). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of CAMP4 THERAPEUTICS CORPORATION

How large is the market capitalisation of CAMP4 THERAPEUTICS CORPORATION (CAMP)?
The market capitalisation of CAMP4 THERAPEUTICS CORPORATION is $294M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CAMP4 THERAPEUTICS CORPORATION (CAMP)?
The price-to-sales ratio of CAMP4 THERAPEUTICS CORPORATION is 55.3 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CAMP4 THERAPEUTICS CORPORATION (CAMP)?
Earnings per share at CAMP4 THERAPEUTICS CORPORATION are $−2.11. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of CAMP4 THERAPEUTICS CORPORATION (CAMP)?
The return on equity (ROE) of CAMP4 THERAPEUTICS CORPORATION is −146% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CAMP4 THERAPEUTICS CORPORATION (CAMP)?
On an EBIT basis the return on assets of CAMP4 THERAPEUTICS CORPORATION is −50.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CAMP4 THERAPEUTICS CORPORATION (CAMP)?
The operating margin of CAMP4 THERAPEUTICS CORPORATION is −739% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CAMP4 THERAPEUTICS CORPORATION (CAMP)?
Revenue at CAMP4 THERAPEUTICS CORPORATION is growing +139% versus a year earlier (3y avg −77.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CAMP4 THERAPEUTICS CORPORATION (CAMP) generate?
The free cash flow of CAMP4 THERAPEUTICS CORPORATION is −$29.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does CAMP4 THERAPEUTICS CORPORATION (CAMP) hold?
CAMP4 THERAPEUTICS CORPORATION holds more cash than debt, $108M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch CAMP4 THERAPEUTICS CORPORATION in the live analysis

One click puts CAMP4 THERAPEUTICS CORPORATION on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.